Can you get Mounjaro on the NHS? Eligibility and UK use figures

The answer depends on where you live, why Mounjaro is being prescribed and which NHS pathway is available. "Approved" does not mean every person who wants it can currently receive it through the NHS.

Mounjaro is the brand name for tirzepatide. In the UK it is authorised for weight management in adults with a BMI of 30 or more, or a BMI of 27 to below 30 with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. It is also authorised for type 2 diabetes. The UK product information sets out the licensed indications.

NICE recommendation and NHS access are different things

NICE recommends tirzepatide as an option for adults with a BMI of at least 35 and at least one weight-related health condition, alongside diet and physical-activity support. NICE uses a lower BMI threshold, usually 2.5 points lower, for some ethnic groups who can develop weight-related health risks at a lower BMI. That is the national recommendation. How and when a medicine is funded and delivered is a separate question.

In England, NHS England introduced a phased primary-care rollout because the eligible population is much larger than the service can treat at once. The first cohort began in June 2025 for people with a BMI of at least 40 and at least four of five specified weight-related conditions: type 2 diabetes, high blood pressure, cardiovascular disease, obstructive sleep apnoea or abnormal blood fats. A second phase began in June 2026, adding people with a BMI from 35 to below 40 who also meet the four-condition threshold. Ethnicity-adjusted BMI thresholds apply. Local commissioning and service capacity affect how people are identified and treated, so check current advice from your GP or local NHS commissioner. See NHS England's interim commissioning guidance and NICE's recommendation.

Those English rollout rules are not a UK-wide appointment timetable. Scotland, Wales and Northern Ireland have their own commissioning arrangements. Private prescribing also follows a different route from NHS eligibility, but should still involve a qualified prescriber, proper assessment and follow-up.

How many people use these medicines?

A UCL analysis of a representative survey of 5,260 adults in England, Wales and Scotland asked about Mounjaro, Ozempic, Wegovy, Rybelsus and Saxenda. Researchers estimated that 1.6 million adults had used one of these medicines for weight loss between early 2024 and early 2025; 910,000 said they used them exclusively for weight loss. Among people reporting medicine use solely for weight loss, four in five reported Mounjaro.

These are survey estimates, not NHS prescription counts and not a Mounjaro-only total. They rely on self-report, cover Great Britain rather than Northern Ireland and do not establish whether a respondent met clinical criteria or received adequate supervision. UCL explains the survey methods and limitations.

The same survey estimated 3.3 million people were interested in using a weight-loss medicine in the next year. Interest is not the same as clinical eligibility, a prescription or a treatment outcome.

What should you do if you are considering it?

If you have type 2 diabetes, discuss diabetes treatment with your usual clinician. If your goal is weight management, ask your GP which local service currently assesses eligibility and what support accompanies treatment. If you are already using a private prescription, arrange follow-up with the prescriber and make sure any other clinician treating you knows about it.

Avoid unprescribed or "research" products. A medicine that is suitable for one person may be unsafe or inappropriate for another, and online use without monitoring can leave problems such as dehydration, low blood sugar or severe abdominal pain without timely care.